Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Br J Dermatol ; 182(5): 1269-1276, 2020 05.
Article in English | MEDLINE | ID: mdl-31392722

ABSTRACT

BACKGROUND: A transition from a subtyping to a phenotyping approach in rosacea is underway, allowing individual patient management according to presenting features instead of categorization by predefined subtypes. The ROSacea COnsensus (ROSCO) 2017 recommendations further support this transition and align with guidance from other working groups. OBJECTIVES: To update and extend previous global ROSCO recommendations in line with the latest research and continue supporting uptake of the phenotype approach in rosacea through clinical tool development. METHODS: Nineteen dermatologists and two ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and management. Voting was electronic and blinded. RESULTS: Delphi statements on which the panel achieved consensus of ≥ 75% voting 'Agree' or 'Strongly agree' are presented. The panel recommends discussing disease burden with patients during consultations, using four questions to assist conversations. The primary treatment objective should be achievement of complete clearance, owing to previously established clinical benefits for patients. Cutaneous and ocular features are defined. Treatments have been reassessed in line with recent evidence and the prior treatment algorithm updated. Combination therapy is recommended to benefit patients with multiple features. Ongoing monitoring and dialogue should take place between physician and patients, covering defined factors to maximize outcomes. A prototype clinical tool (Rosacea Tracker) and patient case studies have been developed from consensus statements. CONCLUSIONS: The current survey updates previous recommendations as a basis for local guideline development and provides clinical tools to facilitate a phenotype approach in practice and improve rosacea patient management. What's already known about this topic? A transition to a phenotype approach in rosacea is underway and is being recommended by multiple working groups. New research has become available since the previous ROSCO consensus, necessitating an update and extension of recommendations. What does this study add? We offer updated global recommendations for clinical practice that account for recent research, to continue supporting the transition to a phenotype approach in rosacea. We present prototype clinical tools to facilitate use of the phenotype approach in practice and improve management of patients with rosacea.


Subject(s)
Ophthalmologists , Rosacea , Combined Modality Therapy , Consensus , Cost of Illness , Humans , Rosacea/diagnosis , Rosacea/therapy
2.
Br J Dermatol ; 179(3): 741-746, 2018 09.
Article in English | MEDLINE | ID: mdl-29799114

ABSTRACT

BACKGROUND: Rosacea diagnosis and classification have evolved since the 2002 National Rosacea Society expert panel subtype approach. Several working groups are now aligned to a more patient-centric phenotype approach, based on an individual's presenting signs and symptoms. However, subtyping is still commonplace across the field and an integrated strategy is required to ensure widespread progression to the phenotype approach. OBJECTIVES: To provide practical recommendations that facilitate adoption of a phenotype approach across the rosacea field. METHODS: A review of the literature and consolidation of rosacea expert experience. RESULTS: We identify challenges to implementing a phenotype approach in rosacea and offer practical recommendations to overcome them across clinical practice, interventional research, epidemiological research and basic science. CONCLUSIONS: These practical recommendations are intended to indicate the next steps in the progression from subtyping to a phenotype approach in rosacea, with the goals of improving our understanding of the disease, facilitating treatment developments and ultimately improving care for patients with rosacea.


Subject(s)
Biomedical Research/organization & administration , Dermatology/organization & administration , Patient-Centered Care/organization & administration , Rosacea/therapy , Biomedical Research/methods , Dermatology/methods , Disease Progression , Humans , Patient-Centered Care/methods , Phenotype , Quality Improvement , Rosacea/diagnosis , Rosacea/genetics , Severity of Illness Index
3.
Int J Obes (Lond) ; 40(9): 1424-34, 2016 09.
Article in English | MEDLINE | ID: mdl-27163748

ABSTRACT

BACKGROUND AND OBJECTIVES: Obesity is a global epidemic which increases the risk of the metabolic syndrome. Cathelicidin (LL-37 and mCRAMP) is an antimicrobial peptide with an unknown role in obesity. We hypothesize that cathelicidin expression correlates with obesity and modulates fat mass and hepatic steatosis. MATERIALS AND METHODS: Male C57BL/6 J mice were fed a high-fat diet. Streptozotocin was injected into mice to induce diabetes. Experimental groups were injected with cathelicidin and CD36 overexpressing lentiviruses. Human mesenteric fat adipocytes, mouse 3T3-L1 differentiated adipocytes and human HepG2 hepatocytes were used in the in vitro experiments. Cathelicidin levels in non-diabetic, prediabetic and type II diabetic patients were measured by enzyme-linked immunosorbent assay. RESULTS: Lentiviral cathelicidin overexpression reduced hepatic steatosis and decreased the fat mass of high-fat diet-treated diabetic mice. Cathelicidin overexpression reduced mesenteric fat and hepatic fatty acid translocase (CD36) expression that was reversed by lentiviral CD36 overexpression. Exposure of adipocytes and hepatocytes to cathelicidin significantly inhibited CD36 expression and reduced lipid accumulation. Serum cathelicidin protein levels were significantly increased in non-diabetic and prediabetic patients with obesity, compared with non-diabetic patients with normal body mass index (BMI) values. Prediabetic patients had lower serum cathelicidin protein levels than non-diabetic subjects. CONCLUSIONS: Cathelicidin inhibits the CD36 fat receptor and lipid accumulation in adipocytes and hepatocytes, leading to a reduction of fat mass and hepatic steatosis in vivo. Circulating cathelicidin levels are associated with increased BMI. Our results demonstrate that cathelicidin modulates the development of obesity.


Subject(s)
Antimicrobial Cationic Peptides/pharmacology , Fatty Liver/drug therapy , Fatty Liver/prevention & control , Lipid Metabolism/drug effects , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Adipocytes/metabolism , Animals , CD36 Antigens/biosynthesis , CD36 Antigens/genetics , Cell Differentiation/drug effects , Diabetes Mellitus, Experimental , Diet, High-Fat/adverse effects , Disease Models, Animal , Fatty Liver/complications , Fatty Liver/metabolism , Gene Expression Regulation/drug effects , Hepatocytes/drug effects , Humans , Immunohistochemistry , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Obesity/complications , Obesity/metabolism , Prediabetic State/complications , Prediabetic State/metabolism , Cathelicidins
5.
Benef Microbes ; 5(2): 161-8, 2014 Jun 01.
Article in English | MEDLINE | ID: mdl-24686580

ABSTRACT

Previously, we demonstrated that Propionibacterium acnes, a human skin commensal bacterium, ferments glycerol into short-chain fatty acids, including propionic acid. Propionic acid suppressed the growth of Staphylococcus aureus USA300, a community-acquired methicillin-resistant bacterium, in vitro and in vivo. In this study, it is demonstrated that the anti-USA300 activity of propionic acid persisted after buffering the acid with 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid. This suggests that the growth suppression of USA300 mainly resulted from the antimicrobial activity of propionic acid per se and not from the acidity of the medium. In addition, proprionic acid significantly reduced the intracellular pH of USA300 and exhibited broad-spectrum antimicrobial activity against Escherichia coli and Candida albicans. P. acnes showed a higher tolerance to propionic acid. Next, an esterified derivative of propionic acid was synthesised. Propionic acid and the esterified derivative were equivalent in their efficacy to suppress the growth of USA300 in vitro. The esterified derivative thus provides an alternative to propionic acid as an antimicrobial agent against S. aureus.


Subject(s)
Anti-Infective Agents/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/growth & development , Propionates/pharmacology , Candida albicans/drug effects , Colony Count, Microbial , Cytoplasm/chemistry , Escherichia coli/drug effects , Hydrogen-Ion Concentration , Microbial Sensitivity Tests , Propionibacterium acnes/drug effects
6.
J Eur Acad Dermatol Venereol ; 28(6): 781-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23638978

ABSTRACT

BACKGROUND: Subjects with atopic dermatitis (AD) have defects in antimicrobial peptide (AMP) production possibly contributing to an increased risk of infections. In laboratory models, vitamin D can alter innate immunity by increasing AMP production. OBJECTIVE: To determine if AD severity correlates with baseline vitamin D levels, and to test whether supplementation with oral vitamin D alters AMP production in AD skin. METHODS: This was a multi-centre, placebo-controlled, double-blind study in 30 subjects with AD, 30 non-atopic subjects, and 16 subjects with psoriasis. Subjects were randomized to receive either 4000 IU of cholecalciferol or placebo for 21 days. At baseline and day 21, levels of 25-hydroxyvitamin D (25OHD), cathelicidin, HBD-3, IL-13, and Eczema Area and Severity Index (EASI) and Rajka-Langeland scores were obtained. RESULTS: At baseline, 20% of AD subjects had serum 25OHD below 20 ng/mL. Low serum 25OHD correlated with increased Fitzpatrick Skin Type and elevated BMI, but not AD severity. After 21 days of oral cholecalciferol, mean serum 25OHD increased, but there was no significant change in skin cathelicidin, HBD-3, IL-13 or EASI scores. CONCLUSIONS: This study illustrated that darker skin types and elevated BMI are important risk factors for vitamin D deficiency in subjects with AD, and highlighted the possibility that seasonality and locale may be potent contributors to cathelicidin induction through their effect on steady state 25OHD levels. Given the molecular links between vitamin D and immune function, further study of vitamin D supplementation in subjects with AD is warranted.


Subject(s)
Cholecalciferol/therapeutic use , Dermatitis, Atopic/drug therapy , Dietary Supplements , Vitamins/therapeutic use , Adult , Dermatitis, Atopic/blood , Double-Blind Method , Female , Humans , Male , Severity of Illness Index , Vitamin D/analogs & derivatives , Vitamin D/blood
7.
Oncogene ; 33(21): 2709-16, 2014 May 22.
Article in English | MEDLINE | ID: mdl-23812430

ABSTRACT

Antimicrobial peptides, such as the cathelicidin LL-37/hCAP-18 and its mouse homolog cathelicidin-related antimicrobial peptide (CRAMP), are important effectors of the innate immune system with direct anti-bacterial activity. Cathelicidin is possibly involved in the regulation of tumor cell growth. The aim of this study was to characterize the role of cathelicidin expressed in non-tumorous cells in a preclinical mouse model of tumor growth. Wild-type and CRAMP-deficient animals were exposed to cigarette smoke (CS) and Lewis lung carcinoma cells were injected to initiate the growth of tumors in the lung. CS exposure significantly increased the proliferation of lung tumors in wild-type mice, but not in CRAMP-deficient mice. CS exposure induced the recruitment of myeloid cell into tumor tissue in a CRAMP-dependent manner. Mice lacking RelA/p65 specifically in myeloid cells showed impaired recruitment of CRAMP-positive cells into the lung. In vitro studies with human cells showed that LL-37/hCAP-18 in macrophages is induced by soluble factors derived from cancer cells. Taken together, these data indicate that cathelicidin expressed from myeloid cells promotes CS-induced lung tumor growth by further recruitment of inflammatory cells. The regulation of cathelicidin expression involves myeloid p65/RelA and soluble factor from tumor cells.


Subject(s)
Carcinoma, Lewis Lung/metabolism , Cathelicidins/biosynthesis , Lung Neoplasms/metabolism , Myeloid Cells/metabolism , Animals , Antimicrobial Cationic Peptides , Carcinoma, Lewis Lung/immunology , Carcinoma, Lewis Lung/secondary , Cell Line, Tumor , Coculture Techniques , Humans , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Macrophages/immunology , Macrophages/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Cells/immunology , Neoplasm Transplantation , Smoking/adverse effects , Transcription Factor RelA/genetics , Transcription Factor RelA/metabolism , Tumor Burden
8.
J Eur Acad Dermatol Venereol ; 27(6): 771-8, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22671985

ABSTRACT

BACKGROUND: Interferon-alpha (IFN-α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN-α is increasingly recognized, but the distinct associated features, aetiology and management have not been reviewed. OBJECTIVE: To review all published cases of hepatitis C patients who developed psoriasis while receiving IFN-α therapy. METHODS: The review was conducted by searching the PubMed database using the keywords 'hepatitis C' AND 'psoriasis.' In addition, references to additional publications not indexed for PubMed were followed to obtain a complete record of published data. RESULTS: We identified 32 publications describing 36 subjects who developed a psoriatic eruption while receiving IFN-α therapy for hepatitis C. Topical therapies were a commonly employed treatment modality, but led to resolution in only 30% of cases in which they were employed solely. Cessation of IFN-α therapy led to resolution in 93% of cases. Hundred per cent of those who developed psoriasis while on IFN-α therapy responded to systemic therapy and were able to continue the drug. CONCLUSION: Further studies and analysis of IFN-α-induced lesions are necessary to clarify the role of IFN-α and the hepatitis C virus in the development of psoriatic lesions.


Subject(s)
Antiviral Agents/adverse effects , Hepatitis C/drug therapy , Interferon-alpha/adverse effects , Psoriasis/chemically induced , Adult , Aged , Disease Progression , Female , Humans , Male , Middle Aged
9.
Gene Ther ; 20(2): 187-93, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22378344

ABSTRACT

Cathelicidin is a pleiotropic host defense peptide secreted by epithelial and immune cells. Whether endogenous cathelicidin is protective against ulcerative colitis, however, is unclear. Here we sought to delineate the role of endogenous murine cathelicidin (mCRAMP) and the therapeutic efficacy of intrarectal administration of mCRAMP-encoding plasmid in ulcerative colitis using dextran sulfate sodium (DSS)-challenged cathelicidin-knockout (Cnlp(-/-)) mice as a model. Cnlp(-/-) mice had more severe symptoms and mucosal disruption than the wild-type mice in response to DSS challenge. The tissue levels of interleukin-1ß and tumor necrosis factor-α, myeloperoxidase activity and the number of apoptotic cells were increased in the colon of DSS-challenged Cnlp(-/-) mice. Moreover, mucus secretion and mucin gene expression were impaired in Cnlp(-/-) mice. All these abnormalities were reversed by the intrarectal administration of mCRAMP or mCRAMP-encoding plasmid. Taken together, endogenous cathelicidin may protect against ulcerative colitis through modulation of inflammation and mucus secretion.


Subject(s)
Antimicrobial Cationic Peptides/genetics , Colitis, Ulcerative/therapy , Genetic Therapy , Administration, Rectal , Animals , Apoptosis , Colitis, Ulcerative/genetics , Gene Expression , Genetic Vectors , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Intestinal Mucosa/pathology , Mice , Mice, Knockout , Mucins/genetics , Mucins/metabolism , Peroxidase/genetics , Peroxidase/metabolism , Plasmids/administration & dosage , Plasmids/genetics , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Cathelicidins
10.
Curr Med Chem ; 20(4): 562-8, 2013.
Article in English | MEDLINE | ID: mdl-23231351

ABSTRACT

Propionibacterium acnes (P. acnes), a Gram-positive anaerobic bacterium, is a commensal organism in human skin. Like human cells, the bacteria produce porphyrins, which exhibit fluorescence properties and make bacteria visible with a Wood's lamp. In this review, we compare the porphyrin biosynthesis in humans and P. acnes. Also, since P. acnes living on the surface of skin receive the same radiation exposure as humans, we envision that the changes in porphyrin profiles (the absorption spectra and/or metabolism) of P. acnes by radiation may mirror the response of human cells to radiation. The porphyrin profiles of P. acnes may be a more accurate reflection of radiation risk to the patient than other biodosimeters/biomarkers such as gene up-/down-regulation, which may be non-specific due to patient related factors such as autoimmune diseases. Lastly, we discuss the challenges and possible solutions for using the P. acnes response to predict the radiation risk.


Subject(s)
Gamma Rays/adverse effects , Porphyrins/metabolism , Propionibacterium acnes/metabolism , Skin/metabolism , Skin/microbiology , Acne Vulgaris/microbiology , Bacterial Typing Techniques , Gram-Positive Bacterial Infections/metabolism , Gram-Positive Bacterial Infections/microbiology , Humans , Porphyrins/biosynthesis , Propionibacterium acnes/genetics , Risk Assessment
11.
Gene Ther ; 20(7): 751-60, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23254369

ABSTRACT

Cathelicidin, an antimicrobial peptide of the innate immune system, has been shown to modulate microbial growth, wound healing and inflammation. However, whether cathelicidin controls Helicobacter pylori infection in vivo remains unexplored. This study sought to elucidate the role of endogenous and exogenous mouse cathelicidin (CRAMP) in the protection against H. pylori infection and the associated gastritis in mice. Results showed that genetic ablation of CRAMP in mice significantly increased the susceptibility of H. pylori colonization and the associated gastritis as compared with the wild-type control. Furthermore, replenishment with exogenous CRAMP, delivered via a bioengineered CRAMP-secreting strain of Lactococcus lactis, reduced H. pylori density in the stomach as well as the associated inflammatory cell infiltration and cytokine production. Collectively, these findings indicate that cathelicidin protects against H. pylori infection and its associated gastritis in vivo. Our study also demonstrates the feasibility of using the transformed food-grade bacteria to deliver cathelicidin, which may have potential clinical applications in the treatment of H. pylori infection in humans.


Subject(s)
Antimicrobial Cationic Peptides , Gastritis/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Animals , Antimicrobial Cationic Peptides/administration & dosage , Antimicrobial Cationic Peptides/genetics , Disease Models, Animal , Drug Delivery Systems , Gastric Mucosa/drug effects , Gastric Mucosa/microbiology , Gastritis/complications , Gastritis/microbiology , Gastritis/pathology , Genetic Vectors , Helicobacter Infections/complications , Helicobacter Infections/microbiology , Helicobacter pylori/growth & development , Helicobacter pylori/pathogenicity , Humans , Inflammation/drug therapy , Inflammation/microbiology , Inflammation/pathology , Lactobacillus/genetics , Mice , Cathelicidins
13.
Br J Dermatol ; 158(3): 442-55, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18275522

ABSTRACT

Microbes found on the skin are usually regarded as pathogens, potential pathogens or innocuous symbiotic organisms. Advances in microbiology and immunology are revising our understanding of the molecular mechanisms of microbial virulence and the specific events involved in the host-microbe interaction. Current data contradict some historical classifications of cutaneous microbiota and suggest that these organisms may protect the host, defining them not as simple symbiotic microbes but rather as mutualistic. This review will summarize current information on bacterial skin flora including Staphylococcus, Corynebacterium, Propionibacterium, Streptococcus and Pseudomonas. Specifically, the review will discuss our current understanding of the cutaneous microbiota as well as shifting paradigms in the interpretation of the roles microbes play in skin health and disease.


Subject(s)
Metagenome/immunology , Microbial Viability/immunology , Skin/microbiology , Corynebacterium diphtheriae/immunology , Female , Gram-Positive Bacterial Infections/immunology , Gram-Positive Cocci/growth & development , Gram-Positive Cocci/immunology , Humans , Male , Metagenome/physiology , Propionibacterium acnes/immunology
14.
Exp Dermatol ; 15(11): 913-29, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17002689

ABSTRACT

Our views of the skin immunity theatre are undergoing constant change. These not only reflect paradigm shifts in general immunology and skin biology, but also have profound clinical implications, which call for strategic changes in dermatological therapy. Nowhere can this be witnessed at a greater level of instructiveness and fascination than when addressing the question posed by this new Controversies feature. Thus, after a very long period of dominance by T cells and Langerhans cells as 'lead actors' on the skin immunity stage, the lowly keratinocyte has recently made an astounding theatrical appearance as a key protagonist of the innate skin immunity system, which may control even acquired skin immune responses. Further enhancing dramatic complexity and tension, the mast cell has entered as an additional actor claiming centre stage, and the epidermal Langerhans cell has slipped in a surprise appearance as the chief agent of immunotolerance. May you, esteemed reader, enjoy the spectacle offered here by selected immunodermatology authorities who double as 'stage managers' pushing their respective favourite actors into the limelight. You get everything you may expect from a good performance - complete with the impresario's overture that lures you into the theatre and sets the stage, competing divas, recently discovered new talents and even the critic's digest while the performance is still ongoing. By the time the curtain drops, you will have reached your own, independent conclusions on how to answer the title question of this play - at least for the time being...


Subject(s)
Dendritic Cells/immunology , Keratinocytes/immunology , Lymphocytes/immunology , Skin/immunology , Humans , Skin/cytology
15.
Curr Top Microbiol Immunol ; 306: 91-110, 2006.
Article in English | MEDLINE | ID: mdl-16909919

ABSTRACT

The skin is positioned at the interface between an organism's internal milieu and an external environment characterized by constant assault with potential microbial pathogens. While the skin was formerly considered an inactive physical protective barrier that participates in host immune defense merely by blocking entry of microbial pathogens, it is now apparent that a major role of the skin is to defend the body by rapidly mounting an innate immune response to injury and microbial insult. In the skin, both resident and infiltrating cells synthesize and secrete small peptides that demonstrate broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses. Antimicrobial peptides also act as multifunctional immune effectors by stimulating cytokine and chemokine production, angiogenesis, and wound healing. Cathelicidins and defensins comprise two major families of skin-derived antimicrobial peptides, although numerous others have been described. Many such immune defense molecules are currently being developed therapeutically in an attempt to combat growing bacterial resistance to conventional antibiotics.


Subject(s)
Antimicrobial Cationic Peptides/physiology , Defensins/physiology , Immunity, Innate , Skin/immunology , Animals , Humans , Immunologic Factors/physiology , Keratinocytes/immunology , Skin Diseases, Bacterial/immunology , Cathelicidins
16.
Exp Dermatol ; 13(8): 505-11, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15265015

ABSTRACT

The N-methyl-D-aspartate (NMDA) receptor is expressed on neural tissue where it gates calcium ion entry upon stimulation. Using immunohistochemistry, it has been demonstrated in this study that the NMDAR1 receptor is also expressed on keratinocytes (KCs) in normal human skin and inflamed psoriatic skin in vivo. Furthermore, the NMDA receptor was functional as demonstrated by the ability of this receptor to trigger Ca++ influx in KCs. Incubation of cultured, human KCs with MK-801 decreases the cell growth and induces an increase in apoptosis. These findings demonstrate that the KC expression of NMDA receptor is a mechanism through which the influx of Ca++ into the cell can be regulated and suggest that the expression of this receptor may play a role in the regulation of KC growth and differentiation.


Subject(s)
Carrier Proteins/biosynthesis , Carrier Proteins/physiology , Keratinocytes/metabolism , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/physiology , Apoptosis , Calcium/metabolism , Cell Differentiation , Cell Proliferation , Dose-Response Relationship, Drug , Epidermis/metabolism , Flow Cytometry , Gene Expression Regulation , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Inflammation , Receptors, N-Methyl-D-Aspartate , Skin/metabolism , Time Factors
17.
J Dent Res ; 81(12): 845-50, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12454100

ABSTRACT

The expression of antimicrobial peptides at epithelial surfaces such as skin, lung, and intestine is thought to provide protection against infection. Cathelicidin antimicrobial peptides are essential for the protection of skin against invasive bacterial infection. To determine if cathelicidins are also present in the oral cavity, we examined the expression of both mRNA and protein in mice and human saliva. The murine cathelicidin (CRAMP) was detected in the adult by reverse-transcription/polymerase chain-reaction (RT-PCR), and in embryonic, newborn, and adult tissues by in situ hybridization and immunohistochemistry. CRAMP mRNA and protein were localized to the salivary glands, specifically in acinar cells of the submandibular gland and palatine minor glands, as well as in lingual epithelium and palatal mucosa. In man, the human cathelicidin LL-37 was detected in human saliva by Western blotting. These results indicate that cathelicidins are present in the salivary system, in some oral epithelia, and in saliva, contributing to broad-spectrum defense of the oral cavity.


Subject(s)
Antimicrobial Cationic Peptides/biosynthesis , Immunity, Mucosal , Mouth Mucosa/immunology , Saliva/immunology , Salivary Glands/immunology , Salivary Proteins and Peptides/biosynthesis , Animals , Antimicrobial Cationic Peptides/immunology , Blotting, Western , Cathelicidins , Gene Expression , Humans , Immunohistochemistry , In Situ Hybridization , Mice , Mice, Inbred BALB C , Mouth Mucosa/metabolism , Protein Biosynthesis , Protein Precursors/biosynthesis , Protein Precursors/immunology , Proteins/immunology , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Saliva/metabolism , Salivary Glands/metabolism , Salivary Proteins and Peptides/immunology
18.
Nature ; 414(6862): 454-7, 2001 Nov 22.
Article in English | MEDLINE | ID: mdl-11719807

ABSTRACT

In mammals, several gene families encode peptides with antibacterial activity, such as the beta-defensins and cathelicidins. These peptides are expressed on epithelial surfaces and in neutrophils, and have been proposed to provide a first line of defence against infection by acting as 'natural antibiotics'. The protective effect of antimicrobial peptides is brought into question by observations that several of these peptides are easily inactivated and have diverse cellular effects that are distinct from antimicrobial activity demonstrated in vitro. To investigate the function of a specific antimicrobial peptide in a mouse model of cutaneous infection, we applied a combined mammalian and bacterial genetic approach to the cathelicidin antimicrobial gene family. The mature human (LL-37) and mouse (CRAMP) peptides are encoded by similar genes (CAMP and Cnlp, respectively), and have similar alpha-helical structures, spectra of antimicrobial activity and tissue distribution. Here we show that cathelicidins are an important native component of innate host defence in mice and provide protection against necrotic skin infection caused by Group A Streptococcus (GAS).


Subject(s)
Antimicrobial Cationic Peptides , Proteins/immunology , Skin Diseases, Bacterial/immunology , Streptococcal Infections/immunology , Streptococcus pyogenes , Animals , Cathelicidins , Drug Resistance, Bacterial/genetics , Female , Immunity, Innate , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mutation , Proteins/genetics , Proteins/pharmacology , Recombinant Fusion Proteins , Streptococcus pyogenes/genetics
19.
Peptides ; 22(10): 1643-50, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11587792

ABSTRACT

Cathelicidins are a mammalian gene family notable for the presence of an antibiotic peptide encoded at the carboxy-terminal domain of the nascent pre-pro-protein. Following proteolytic release, this peptide has direct antimicrobial activity. To understand the function and regulation of cathelicidin we investigated the peptide processing site and gene structure of the mouse cathelicidin CRAMP. Amino acid sequencing of the purified native 5 kDa peptide identified the functionally critical amino terminal sequence of mature CRAMP. Characterization of the CRAMP gene (Cnlp) showed homology in structure and sequence identity in several potential transcription factors binding sites found in the human cathelicidin LL-37. Overall, CRAMP shows striking similarities with LL-37, making it a useful model for study of human cathelicidin function and regulation.


Subject(s)
Antimicrobial Cationic Peptides/genetics , Antimicrobial Cationic Peptides/isolation & purification , Blood Proteins/genetics , Genes/genetics , Protein Precursors/genetics , Animals , Antimicrobial Cationic Peptides/metabolism , Base Sequence/genetics , Binding Sites/genetics , Binding Sites/physiology , Blood Proteins/immunology , Blood Proteins/metabolism , Bone Marrow/metabolism , Genes/physiology , Humans , Mice , Models, Biological , Molecular Sequence Data , Prodrugs/metabolism , Protein Precursors/immunology , Protein Precursors/metabolism , Transcription Factors/genetics
20.
J Invest Dermatol ; 117(1): 91-7, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11442754

ABSTRACT

Cathelicidins are a family of peptides thought to provide an innate defensive barrier against a variety of potential microbial pathogens. The human and mouse cathelicidins (LL-37 and CRAMP, respectively) are expressed at select epithelial interfaces where they have been proposed to kill a number of gram-negative and gram-positive bacteria. To determine if these peptides play a part in the protection of skin against wound infections, the anti-microbial activity of LL-37 and CRAMP was determined against the common wound pathogen group A Streptococcus, and their expression was examined after cutaneous injury. We observed a large increase in the expression of cathelicidins in human and murine skin after sterile incision, or in mouse following infection by group A Streptococcus. The appearance of cathelicidins in skin was due to both synthesis within epidermal keratinocytes and deposition from granulocyctes that migrate to the site of injury. Synthesis and deposition in the wound was accompanied by processing from the inactive prostorage form to the mature C-terminal peptide. Analysis of anti-microbial activity of this C-terminal peptide against group A Streptococcus revealed that both LL-37 and CRAMP potently inhibited bacterial growth. Action against group A Streptococcus occurred in conditions that typically abolish the activity of anti-microbial peptides against other organisms. Thus, cathelicidins are well suited to provide defense against infections due to group A Streptococcus, and represent an important element of cutaneous innate immunity.


Subject(s)
Antimicrobial Cationic Peptides/metabolism , Proteins/metabolism , Skin/injuries , Streptococcal Infections/metabolism , Streptococcus pyogenes , Amino Acid Sequence , Animals , Antimicrobial Cationic Peptides/genetics , Cathelicidins , Female , Gene Expression/physiology , Humans , Keratinocytes/metabolism , Keratinocytes/microbiology , Male , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Proteins/genetics , RNA, Messenger/analysis , Skin/microbiology , Wound Healing/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...